Aktie A403UF CLINICAL LASERTHERMIA SYSTEMS AB
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Clinical Laserthermia Systems AB

Aktien

A403UF

SE0022049920

CLS B

Markt geschlossen - Nasdaq Stockholm
Andere Börsenplätze
 17:22:25 03.05.2024 		% 5 Tage % 1. Jan.
16,25 SEK -0,67 % Intraday Chart für Clinical Laserthermia Systems AB -5,41 % -41,12 %
30.04. Clinical Laserthermia erhält US FDA-Zulassung für das Prism Bone Anchor Accessory von ClearPoint MT
11.04. Clinical Laserthermia Systems AB (publ) präsentiert erste Daten aus der Investigator Initiated Trial (IIT) am Radboud University Medical Center unter Verwendung des CLS Transberg Systems CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory
CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators
Clinical Laserthermia Systems announces timetable and additional information for the upcoming reverse share split
Bulletin from the Extraordinary General Meeting on Friday 12th of April in Clinical Laserthermia Systems AB
BioStock: CLS makes progress in prostate cancer in Europe and the US
Initial data presented from the Investigator Initiated Trial (IIT) at Radboud University Medical Center using the CLS TRANBERG[®] system
Clinical Laserthermia Systems AB Presents Initial Data from the Investigator Initiated Trial at Radboud University Medical Center Using the CLS Transberg System
CLS receives second order from the National Institutes of Health Clinical Center in the US
Clinical Laserthermia Systems Receives Second Order from the National Institutes of Health Clinical Center in the US for its TRANBERG Thermal Therapy System Accessories
As part of CLS expansion in Europe prostate cancer patients have been treated with CLS TRANBERG Thermal Therapy System for the first time in Italy
Clinical Laserthermia Systems AB Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy
CLS signs agreement with ROSE Urology for treatment of prostate cancer patients with TRANBERG Thermal Therapy System
Clinical Laserthermia Systems AB's Subsidiary CLS Americas Signs Agreement with ROSE Urology for Treatment of Prostate Cancer Patients with TRANBERG Thermal Therapy System
Clinical Laserthermia Systems Names Interim CFO
CLS appoints Håkan Rosqvist as interim CFO
Clinical Laserthermia Systems AB Announces CFO Changes
Notice of Extraordinary General Meeting at Clinical Laserthermia Systems AB
Publication in Journal of Neurosurgery Demonstrates Distinct Advantages of CLS's Core Technology in Neurosurgical MR-guided Laser Ablation
Clinical Laserthermia Systems AB Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System
BioStock: CLS sees opportunity to increase revenue
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A403UF Aktie
  4. Nachrichten Clinical Laserthermia Systems AB
  5. Andere Sprachen